Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Jingrui Chen, Jing Wei, Peng Xia, Yuening Liu, Mahder Dawit Belew, Ryan Toohill, Boyang Jason Wu, Zhaokang Cheng
AIMS: The anthracycline family of anticancer agents such as doxorubicin (DOX) can induce apoptotic death of cardiomyocytes and cause cardiotoxicity. We previously reported that DOX-induced apoptosis is accompanied by cardiomyocyte cell cycle-reentry. Cell cycle progression requires cyclin-dependent kinase 7 (CDK7)-mediated activation of downstream cell cycle CDKs. This study aims to determine whether CDK7 can be targeted for cardioprotection during anthracycline chemotherapy. METHODS AND RESULTS: DOX exposure induced CDK7 activation in mouse heart and isolated cardiomyocytes...
April 22, 2024: Cardiovascular Research
#2
JOURNAL ARTICLE
M C Liefaard, A van der Voort, M van Seijen, B Thijssen, J Sanders, S Vonk, L Mittempergher, R Bhaskaran, L de Munck, A E van Leeuwen-Stok, R Salgado, H M Horlings, E H Lips, G S Sonke
Tumor-infiltrating lymphocytes (TILs) have been associated with outcomes in HER2-positive breast cancer patients treated with neoadjuvant chemotherapy and trastuzumab. However, it remains unclear if TILs could be a prognostic and/or predictive biomarker in the context of dual HER2-targeting treatment. In this study, we evaluated the association between TILs and pathological response (pCR) and invasive-disease free survival (IDFS) in 389 patients with stage II-III HER2 positive breast cancer who received neoadjuvant anthracycline-containing or anthracycline-free chemotherapy combined with trastuzumab and pertuzumab in the TRAIN-2 trial...
April 18, 2024: NPJ Breast Cancer
#3
JOURNAL ARTICLE
Riya Garg, Ralph B D'Agostino, Nathaniel O'Connell, Glenn J Lesser, Fadi N Salloum, Anika L Hines, Giselle C Meléndez, Jennifer H Jordan, Bonnie Ky, Lynne I Wagner, Arnethea L Sutton, Wendy Bottinor, Kristine Olson, Amy C Ladd, W Gregory Hundley
BACKGROUND: Hypertension is a risk factor for experiencing left ventricular ejection fraction (LVEF) declines during receipt of potentially cardiotoxic breast cancer (BC) treatment. We sought to determine whether the hypertension stage is associated with LVEF decline during BC treatment. METHODS: Across 24 centers, cardiac magnetic resonance measures of LVEF and brachial arterial blood pressure (BP) measurements were performed in women with stages I to III BC before and 3 months after initiating potentially cardiotoxic chemotherapy...
April 18, 2024: Hypertension
#4
Ying Chen, Wen-Xia Li, Jia-Hua Wu, Geng-Hang Chen, Chun-Min Yang, Hai Lu, Xi Wang, Shu-Sen Wang, Heng Huang, Li Cai, Li Zhao, Rou-Jun Peng, Ying Lin, Jun Tang, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, An-Qin Zhang, Fei Xu, Xi-Wen Bi, Jia-Jia Huang, Ji-Bin Li, Dan-Mei Pang, Cong Xue, Yan-Xia Shi, Zhen-Yu He, Huan-Xin Lin, Xin An, Wen Xia, Ye Cao, Ying Guo, Ruo-Xi Hong, Kui-Kui Jiang, Yong-Yi Zhong, Ge Zhang, Piyawan Tienchaiananda, Masahiro Oikawa, Zhong-Yu Yuan, Qian-Jun Chen
PURPOSE: Results from studies of extended capecitabine after the standard adjuvant chemotherapy in early stage triple-negative breast cancer (TNBC) were inconsistent, and only low-dose capecitabine from the SYSUCC-001 trial improved disease-free survival (DFS). Adjustment of the conventional adjuvant chemotherapy doses affect the prognosis and may affect the efficacy of subsequent treatments. This study investigated whether the survival benefit of the SYSUCC-001 trial was affected by dose adjustment of the standard adjuvant chemotherapy or not...
2024: Breast Cancer: Targets and Therapy
#5
JOURNAL ARTICLE
Darshini Desai, Mohammed Majrashi, Suhrud Pathak, Mohammed Almaghrabi, Keyi Liu, Satyanarayana R Pondugula, Amit K Tiwari, R Jayachandra Babu, Jack Deruiter, Muralikrishnan Dhanasekaran
BACKGROUND: Iatrogenesis is an inevitable global threat to healthcare that drastically increases morbidity and mortality. Cancer is a fatal pathological condition that affects people of different ages, sexes, and races around the world. In addition to the detrimental cancer pathology, one of the most common contraindications and challenges observed in cancer patients is severe adverse drug effects and hypersensitivity reactions induced by chemotherapy. Chemotherapy-induced cognitive neurotoxicity is clinically referred to as Chemotherapy-induced cognitive impairment (CICI), chemobrain, or chemofog...
April 2024: Cancer reports
#6
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
April 16, 2024: European Heart Journal
#7
JOURNAL ARTICLE
Marta Sevieri, Francesco Andreata, Francesco Mainini, Lorena Signati, Francesca Piccotti, Marta Truffi, Arianna Bonizzi, Leopoldo Sitia, Claudia Pigliacelli, Carlo Morasso, Barbara Tagliaferri, Fabio Corsi, Serena Mazzucchelli
Despite the advent of numerous targeted therapies in clinical practice, anthracyclines, including doxorubicin (DOX), continue to play a pivotal role in breast cancer (BC) treatment. DOX directly disrupts DNA replication, demonstrating remarkable efficacy against BC cells. However, its non-specificity toward cancer cells leads to significant side effects, limiting its clinical utility. Interestingly, DOX can also enhance the antitumor immune response by promoting immunogenic cell death in BC cells, thereby facilitating the presentation of tumor antigens to the adaptive immune system...
April 15, 2024: Journal of Nanobiotechnology
#8
So-Young Lee, Hoon Seok Kim, Mi-Hyang Jung, Suyon Chang, Myungshin Kim, Jong-Chan Youn, Woo-Baek Chung, Hae Ok Jung
The prevention and management of cancer therapy-related cardiac dysfunction (CTRCD) have become increasingly important. Recent studies have revealed the crucial role of genetics in determining the susceptibility to development of CTRCD. We present a case of a 65-year-old woman with breast cancer who developed recurrent CTRCD following low-dose chemotherapy, despite lacking conventional cardiovascular risk factors. Her medical history included anthracycline-associated cardiomyopathy, and her condition deteriorated significantly after treatment with HER2-targeted therapies...
April 14, 2024: ESC Heart Failure
#9
JOURNAL ARTICLE
Ludovico Rossetto, Daniela Di Lisi, Cristina Madaudo, Francesco Paolo Sinagra, Antonio Di Palermo, Oreste Fabio Triolo, Grazia Gambino, Antonella Ortello, Alfredo Ruggero Galassi, Giuseppina Novo
BACKGROUND: Anthracyclines can cause left ventricular (LV) dysfunction. There is little data about right ventricular (RV) damage during chemotherapy. AIM: This study aimed to investigate the toxic effects of chemotherapy, analyzing its impact on right ventricular function. MATERIAL AND METHODS: A prospective study was conducted, enrolling 83 female patients (55 ± 11 years old) affected by breast cancer treated with anthracyclines...
April 15, 2024: Cardio-Oncology
#10
JOURNAL ARTICLE
Laura Orlando, Evaristo Maiello, Michele Orditura, Anna Diana, Giuliano Antoniol, Maria Grazia Morritti, Michele Aieta, Mariangela Ciccarese, Salvatore Pisconti, Roberto Bordonaro, Antonio Russo, Antonio Febbraro, Paola Schiavone, Annamaria Quaranta, Chiara Caliolo, Dario Loparco, Margherita Cinefra, Giuseppe Colucci, Saverio Cinieri
BACKGROUND: Optimizing chemotherapy to achieve disease and symptoms control is a noteworthy purpose in advanced breast cancer (ABC). We reported the activity and quality of life of a phase II study, comparing metronomic regimen with standard schedule as first line chemotherapy for ABC. METHODS: Patients with HER2 negative ABC were randomized to non-pegylated liposomal doxorubicin (NPLD, 60 mg/m2 every 3 weeks) and cyclophosphamide (CTX, 600 mg/m2 every 3 weeks) (Arm A) or NPLD (20 mg/m2 day, on day 1, 8 and 15 every 4 weeks) and metronomic daily oral CTX 50 mg (ARM B)...
April 5, 2024: Breast: Official Journal of the European Society of Mastology
#11
JOURNAL ARTICLE
Ji He, Jiawei Li, Yanbiao Liu, Yan Li
Sperm-associated antigen 5 (SPAG5), also known as Astrin, was previously demonstrated as a biomarker for cellular resistance to major breast cancer therapies, including chemo-, endocrine- and targeted therapy. However, the contribution of SPAG5 to anthracycline- and taxane-based chemotherapy in triple-negative breast cancer (TNBC) remains controversial. In the present study, the SPAG5 knockout cell model was established by using clustered regularly interspaced palindromic repeats (CRISPR)-CRISPR-associated protein 9 (Cas9) system in MDA-MB-231 and BT549 TNBC cell lines...
March 24, 2024: Cancers
#12
REVIEW
Fausto Petrelli, Antonio Ghidini, Carmen Rea, Maria Chiara Parati, Karen Borgonovo, Michele Ghidini, Fiorella Ruatta, Alberto Zaniboni, Andrea Luciani, Ornella Garrone, Gianluca Tomasello
INTRODUCTION: There are multiple neoadjuvant regimens, including platinum agents for triple-negative breast cancer (TNBC), each with a different safety profile, outcome, and pathologic complete response rate (pCR%). We performed a systematic review and network meta-analysis to compare the efficacy and safety of different platinum-based neoadjuvant CT treatments for TNBC. METHODS: Bibliographic databases (PubMed, Embase, and Cochrane Library) were searched from their inception to October 31, 2022...
April 11, 2024: Current Problems in Cancer
#13
JOURNAL ARTICLE
Suresh Babu, Akansha Choudhary, Linu Jacob, Lokesh K N, Rudresha A H, Rajeev L K, Smitha Saldanha, Usha Amirtham, Vijay C R
Purpose Triple-negative breast cancer (TNBC) has a poor outcome compared to other subtypes. Immune checkpoint inhibitors (ICIs) have changed the treatment paradigm in metastatic diseases as well as in neoadjuvant setting. The response to these agents is affected by programmed death ligand 1 (PDL1) receptor expression which are reported objectively as a score. PDL1 is a prognostic marker also. Here, we present clinicopathological characteristics of metastatic TNBCs, report the proportion of PDL1 expression and its association with clinicopathological factors as well as survival...
March 2024: Curēus
#14
JOURNAL ARTICLE
Zhilin Liu, Jinming Li, Fuxing Zhao, Dengfeng Ren, Zitao Li, Yongzhi Chen, Shifen Huang, Zhen Liu, Yi Zhao, Miaozhou Wang, Huihui Li, ZhengBo Xu, Guoshuang Shen, Jiuda Zhao
BACKGROUND: Triple-negative breast cancer (TNBC) is a life-threatening subtype of breast cancer with limited treatment options. Therefore, this network meta-analysis (NMA) aimed to evaluate and compare the effect of various neoadjuvant chemotherapy (NCT) options on the long-term survival of patients with TNBC. METHODS: PubMed, Embase, Medline, Cochrane Library, Web of Science, and major international conference databases were systematically searched for randomized controlled trials (RCTs) on the efficacy of various NCT options in patients with TNBC...
April 9, 2024: BMC Cancer
#15
JOURNAL ARTICLE
Jean E Abraham, Karen Pinilla, Alimu Dayimu, Louise Grybowicz, Nikolaos Demiris, Caron Harvey, Lynsey M Drewett, Rebecca Lucey, Alexander Fulton, Anne N Roberts, Joanna R Worley, Anita Chhabra, Wendi Qian, Anne-Laure Vallier, Richard M Hardy, Steve Chan, Tamas Hickish, Devashish Tripathi, Ramachandran Venkitaraman, Mojca Persic, Shahzeena Aslam, Daniel Glassman, Sanjay Raj, Annabel Borley, Jeremy P Braybrooke, Stephanie Sutherland, Emma Staples, Lucy C Scott, Mark Davies, Cheryl A Palmer, Margaret Moody, Mark J Churn, Jacqueline C Newby, Mukesh B Mukesh, Amitabha Chakrabarti, Rebecca R Roylance, Philip C Schouten, Nicola C Levitt, Karen McAdam, Anne C Armstrong, Ellen R Copson, Emma McMurtry, Marc Tischkowitz, Elena Provenzano, Helena M Earl
PARTNER is a prospective, phase II-III, randomised controlled clinical trial, which recruited patients with Triple Negative Breast Cancer (TNBC)1,2 , who were gBRCA wild type (gBRCAwt)3 . Patients (n=559) were randomised on a 1:1 basis to neoadjuvant carboplatin with paclitaxel +/- olaparib 150mg twice daily, days 3 to 14, for 4 cycles (gap schedule olaparib, research arm) followed by 3 cycles of anthracycline chemotherapy before surgery. The primary endpoint was pathological complete response (pCR)4 , and secondary endpoints included event-free survival (EFS), and overall survival (OS)5 ...
April 8, 2024: Nature
#16
JOURNAL ARTICLE
Cho Han Chiang, Yu-Cheng Chang, Yulin Haw, Jia Yi Tan, Cho-Hsien Chiang, Yuan Ping Hsia, Cho-Hung Chiang
No abstract text is available yet for this article.
April 5, 2024: Journal of the National Comprehensive Cancer Network: JNCCN
#17
JOURNAL ARTICLE
Nurul Wafiqah Saipol Bahrin, Siti Nur Idayu Matusin, Aklimah Mustapa, Lu Zen Huat, Sriyani Perera, Mas Rina Wati Haji Abdul Hamid
BACKGROUND: Breast cancer incidence has been on the rise significantly in the Asian population, occurring at an earlier age and a later stage. The potential predictive value of molecular subtypes, biomarkers, and genetic variations has not been deeply explored in the Asian population. This study evaluated the effect of molecular subtype classification and the presence or absence of biomarkers and genetic variations on pathological complete response (pCR) after neoadjuvant treatment in Asian breast cancer patients...
April 4, 2024: Systematic Reviews
#18
JOURNAL ARTICLE
Igor Makhlin, Biniyam G Demissei, Ralph D'Agostino, W Greg Hundley, Camelia Baleanu-Gogonea, Nicholas S Wilcox, Anna Chen, Amanda M Smith, Nathaniel Sean O'Connell, James Januzzi, Glenn J Lesser, Marielle Scherrer-Crosbie, Borja Ibáñez, W H Wilson Tang, Bonnie Ky
PURPOSE: Preventing Anthracycline Cardiovascular Toxicity with Statins (PREVENT) (NCT01988571) randomized breast cancer or lymphoma patients receiving anthracyclines to atorvastatin 40 mg daily or placebo. We evaluated the effects of atorvastatin on oxidative and nitrosative stress biomarkers, and explored whether these biomarkers could explain the lack of effect of atorvastatin on LVEF in PREVENT. PATIENTS AND METHODS: Blood samples were collected and cardiac magnetic resonance imaging was performed prior to doxorubicin initiation and at 6 and 24 months...
April 4, 2024: Clinical Cancer Research
#19
JOURNAL ARTICLE
Mangesh Mekha, Ashish Joshi, Vashishth Maniar, Udip Maheshwari, Kshitij Joshi, Pritam Kalaskar, Smit Sheth, Pradip Kendre, Disha Morzaria, Reshma Korgavkar, Chandrashekhar Pethe, Sonal Dhande
AIM: Chemotherapy-induced alopecia (CIA) is the most common side effect of systemic treatment in breast cancer patients. Scalp cooling gained worldwide acceptance in preventing or mitigating CIA in patients undergoing chemotherapy. The objective of this study was to evaluate the efficacy and safety of the Paxman scalp cooling system (PSCS) in Indian breast cancer patients. MATERIALS AND METHODS: This is a multi-centre, retrospective-observational study including patients registered from 1st March, 2019 to 30th April, 2021 undergoing chemotherapy for breast cancer by using PSCS...
2024: Indian Journal of Dermatology
#20
JOURNAL ARTICLE
Surjeet Dwivedi, Amiy Arnav, Varun Kumar Agarwal, S K Deshpande, Rohit Sharma, Naresh Saidha
OBJECTIVE: The most dreaded long-term complication of axillary lymph node dissection remains upper arm lymphedema. Our study has strategized the three most common identified causes of post treatment arm lymphedema, i.e., obesity, radiation, and neoadjuvant chemotherapy and tried to identify the histopathological and clinical or surgical factors which can predict arm lymphedema. MATERIALS AND METHODS: This is a prospective observational study was conducted at a tertiary care referral centre in India, with strict inclusion criteria of BMI <30 kg/m2 , age <75 years, presence of metastatic axillary node proven by FNAC, received anthracycline based neoadjuvant chemotherapy and postoperative nodal irradiation, and completed 24 months of regular follow-up...
April 2024: European Journal of Breast Health
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
